Despite being safe, spinal cord stimulation does not lead to significant improvements in mobility in patients with advanced Parkinson’s disease, including those taking levodopa, a prospective trial has found. The trial findings were reported in the study, “Spinal Cord Stimulation for Very Advanced Parkinson’s Disease:…
Scientists have created a device that allows them to accurately measure the levels of different pro-inflammatory cytokines — molecules that mediate and regulate immune and inflammatory responses — normally found in the brain of patients with Parkinson’s disease. According to researchers, the new device may be used in…
Use of duloxetine, a treatment for depression and nerve pain, fails to alleviate pain in people with Parkinson’s disease, according to data from a clinical trial. However, results also showed that it may be of benefit in easing motor symptoms and improving patients’ quality of life, although more…
Mutations in a gene called ATP10B may increase the risk of developing Parkinson’s disease, a study has found. When mutated, ATP10B is no longer able to provide instructions to make a functional protein that is necessary to transport a fatty substance — known…
Scientists have discovered a series of rare variants in genes that control the function of lysosomes — cell compartments responsible for digesting and recycling different types of molecules — that are associated with Parkinson’s disease. The findings were published in an article, “Rare Variants in…
A probiotic strain of the bacteria Bacillus subtilis called PXN21 can prevent the buildup of the protein alpha-synuclein — one of the hallmarks of Parkinson’s disease — in the round worm C. elegans, researchers reports. This finding warrants further investigation to assess the therapeutic potential of dietary…
Despite being safe and well-tolerated, foliglurax (PTX002331), an investigational therapy for Parkinson’s disease, failed to significantly reduce some of the effects associated with long-term use of levodopa, including its “wearing-off” effect and motor complications, according to data from a Phase 2 clinical trial. As a result,…
Activated immune T-cells can infiltrate the brain and promote neurodegeneration in non-human primate models of Parkinson’s during the chronic stages of the disease, a study has found. Results of the study, “Chronic infiltration of T lymphocytes into the brain in a non-human primate model of Parkinson’s disease,”…
A potential oral therapy for Parkinson’s disease and amyotrophic lateral sclerosis (ALS) was seen to be safe and well-tolerated at various doses in a Phase 1 trial in healthy volunteers, its developer, Neuropore Therapies, announced. Steps are now underway to allow…
Tasigna (nilotinib), an approved leukemia medication being tested as a repurposed treatment for Parkinson’s disease, was found to be safe and increased the levels of dopamine in the brain of patients with Parkinson’s disease, a Phase 2 trial shows. The findings were reported in a study, “Nilotinib…
Get regular updates to your inbox.